The PPARγ K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment

Cancer Letters

Volumn 224, Issue 1, 2005, Pages 111-116

  Bouancheau, Delphine ^a   Buecher, Bruno ^b   Jarry, Anne ^a   Simon, Barbara ^c   Masson, Damien ^a   Cassagnau, Elisabeth ^a   Hamelin, Richard ^d   Laboisse, Christian L ^a   Bézieau, Stéphane ^c   Denis, Marc G ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Allele specific PCR; Colon cancer; Mutation; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANALYTIC METHOD; ARTICLE; CANCER SCREENING; COLON CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; DRUG EFFICACY; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMANS; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 21144442203     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.10.011     Document Type: Article

References (14)

1. H.P. Koeffler Peroxisome proliferator-activated receptor gamma and cancers Clin. Cancer Res. 9 2003 1 9
2. L. Michalik, B. Desvergne, and W. Wahli Peroxisome-proliferator-activated receptors and cancers: complex stories Nat. Rev. Cancer 4 2004 61 70
3. P. Sarraf, E. Mueller, D. Jones, F.J. King, D.J. Deangelo, and J.B. Partridge Differentiation and reversal of malignant changes in colon cancer through PPARgamma Nat. Med. 4 1998 1046 1052
4. T. Tanaka, H. Kohno, S. Yoshitani, S. Takashima, A. Okumura, A. Murakami, and M. Hosokawa Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Res. 61 2001 2424 2428
5. M.H. Kulke, G.D. Demetri, N.E. Sharpless, D.P. Ryan, R. Shivdasani, and J.S. Clark A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer Cancer J. 8 2002 395 399
6. P. Sarraf, E. Mueller, W.M. Smith, H.M. Wright, J.B. Kum, and L.A. Aaltonen Loss-of-function mutations in PPAR gamma associated with human colon cancer Mol. Cell 3 1999 799 804
7. T. Ikezoe, C.W. Miller, S. Kawano, A. Heaney, E.A. Williamson, and J. Hisatake Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies Cancer Res. 61 2001 5307 5310
8. R.A. Gupta, P. Sarraf, E. Mueller, J.A. Brockman, J.J. Prusakiewicz, and C. Eng Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms J. Biol. Chem. 278 2003 22669 22677
9. B. Buecher, M.F. Heymann, A. Lievre, J.M. Nguyen, K. Wilson, and S. Bezieau Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement Aliment. Pharmacol. Ther. 18 2003 731 740
10. G.D. Demetri, C.D. Fletcher, E. Mueller, P. Sarraf, R. Naujoks, and N. Campbell Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc. Natl Acad. Sci. USA 96 1999 3951 3956
11. E. Mueller, M. Smith, P. Sarraf, T. Kroll, A. Aiyer, and D.S. Kaufman Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer Proc. Natl Acad. Sci. USA 97 2000 10990 10995
12. G.D. Girnun, W.M. Smith, S. Drori, P. Sarraf, E. Mueller, and C. Eng APC-dependent suppression of colon carcinogenesis by PPAR gamma Proc. Natl Acad. Sci. USA 99 2002 13771 13776
13. Y. Ohnuki, R.R. Reddel, S.E. Bates, T.A. Lehman, J.F. Lechner, and C.C. Harris Chromosomal changes and progressive tumorigenesis of human bronchial epithelial cell lines Cancer Genet. Cytogenet. 92 1996 99 110
14. P.M. Pollock, G.J. Walker, J.M. Glendening, T. Que Noy, N.C. Bloch, J.W. Fountain, and N.K. Hayward PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines Melanoma Res. 12 2002 565 575